查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2019276

全球藥物濫用治療市場：依治療類型、應用及地區分類的分析－市場規模、產業趨勢、機會分析及2026-2035年預測

Global Substance Abuse Treatment Market: Analysis By Treatment Type, End-use, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

藥物濫用治療市場正經歷快速成長，預計到 2025 年市場規模將達到 157.2 億美元，到 2035 年將達到 394.9 億美元。這一成長意味著在 2026 年至 2035 年的預測期內，複合年成長率高達 9.65%，凸顯了在全球範圍內解決藥物濫用障礙問題日益嚴峻和迫切的需求。

推動這一上升趨勢的關鍵因素有很多。不同人群成癮率的上升顯著擴大了患者群體，從而對住院和門診治療服務產生了持續的需求。同時，遠端醫療平台、數位療法和數據驅動型護理模式等技術進步正在改變治療的提供方式，提高治療的可及性和改善患者的治療效果。

顯著的市場趨勢

藥物濫用治療市場經歷了重大的結構性轉型，從小規模獨立服務提供者高度分散的生態系統，轉變為由少數大型、有影響力的企業主導的更一體化的結構。這種演變造就了寡占的局面，大規模全通路醫療保健機構和資金雄厚的數位顛覆者對當地的定價、服務模式和臨床標準擁有顯著的影響力。

塑造這一全新市場動態的主要企業包括Acadia Healthcare和Universal Health Services。這兩家公司均透過大規模合資企業和策略擴張舉措推動收入成長。憑藉其廣泛的醫療機構網路和規模優勢，它們正在最佳化成本、擴大服務範圍並增強在多個地區的競爭力。在非營利領域，Hazelden Betty Ford基金會透過提供高品質、品牌化的醫療服務，在高階醫療領域佔據主導地位，吸引了許多尋求全面可靠治療方案的患者。

同時，像Groups Recover Together這樣以創新為驅動的新興參與企業正在重塑門診輔助性治療（MAT）領域。這些機構利用科技驅動的醫療服務和高度擴充性的門診模式，正在重新定義成癮治療的可近性和效率。

主要成長要素

由於用戶層迅速擴大，以及可及且及時的治療服務持續短缺，藥物濫用治療的需求正以前所未有的速度成長。據估計，全球約有3,950萬人患有嚴重的藥物濫用障礙，問題的嚴重性和對有效治療基礎設施的迫切需求令人震驚。儘管人們的意識不斷提高，政策制定者也日益重視，但許多地區仍面臨著服務能力不足、資金限制和就醫障礙等問題，導致人們無法獲得所需的治療。

新機會的趨勢

Z世代正帶著極為複雜的臨床特徵進入藥物濫用治療市場。他們常常同時服用多種合成藥物，常伴隨嚴重的精神疾病，包括臨床憂鬱症和急性焦慮症。與前幾代人不同，Z世代重視的治療模式不僅要臨床有效，還要具有創傷敏感性、文化敏感性，並能包容多元身分。他們期望的治療環境能反映社會在醫療保健領域向整體性和個人化轉變的趨勢，並以技術為驅動，高效便捷，且明確支持LGBTQ+群體。

最佳化障礙

藥物濫用治療市場擴張面臨的最大障礙是合格人員的嚴重短缺。目前，該產業正面臨關鍵臨床專業人員25%的供不應求，其中包括成癮精神科醫生、精神科執業護理師和執照臨床社會工作者（LCSW）。這種長期短缺給人員配置模式帶來了巨大壓力，並對整個營運和財務結構產生了連鎖反應。過去三年，由於缺乏熟練的專業人員，臨床人員的薪資上漲了約18%，這進一步加劇了預算緊張，並增加了醫療保健服務的成本。

目錄

第1章執行摘要：全球藥物濫用治療市場

第2章：報告概述

  • 研究框架
    • 研究目標
    • 市場的定義
    • 市場區隔
  • 調查方法
    • 市場規模估算
    • 定性研究
    • 量化研究
    • 按地區分類的主要調查受訪者組成
    • 數據檢驗
    • 調查的前提

第3章：全球藥物濫用治療市場概覽

  • 產業價值鏈分析
    • 原料（活性藥物成分、添加物）
    • 藥物研發和製劑（解毒劑、輔助性治療）
    • 生產（片劑、注射劑、植入）
    • 治療方案的發展（住院治療、門診治療、行為治療）
    • 服務提供者（復健中心、醫院、診所）
    • 分銷通路（藥局、線上平台、向醫療機構供貨）
    • 最終使用者（患者、復健中心、醫療保健提供者）
  • 產業展望
    • 全球物質使用疾患流行病學
    • 目前的治療狀態（藥物治療和行為療法結合）
    • 成癮治療的醫療基礎設施（康復中心和診所的可用性）
    • 所採用的治療方法（住院治療、門診治療或數位化治療）
    • 公共部門和私營部門在醫療保健服務中的作用。
    • 目前產品線狀況（新興治療方法和臨床開發）
    • 報銷方案和保險範圍
    • 監理情勢和政策趨勢
  • PESTLE分析
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場成長及前景
    • 市場收入估算與預測（2020-2035 年）
  • 市場吸引力分析
    • 透過治療方法
  • 可執行的見解（分析師建議）

第4章：競爭對手儀錶板

  • 市場集中度
  • 企業市場占有率分析
  • 競爭格局分析與基準測試

第5章：全球藥物濫用治療市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測（2020-2035）
    • 治療類型
      • 關鍵見解
        • 煙草/尼古丁和電子菸
        • 酒精
        • 大麻
        • 合成大麻素
        • 處方藥和非處方藥
        • 其他
    • 透過使用
      • 關鍵見解
        • 醫院
        • 診所
        • 復健中心
        • 其他
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 西歐其他地區
          • 東歐
            • 波蘭
            • 俄羅斯
            • 東歐其他地區
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 韓國、澳洲和紐西蘭
          • ASEAN
            • 印尼
            • 馬來西亞
            • 泰國
            • 新加坡
            • 其他東協國家
            亞太其他地區
        • 中東和非洲
          • 阿拉伯聯合大公國
          • 沙烏地阿拉伯
          • 南非
          • 其他中東和非洲地區
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地區

第6章：北美藥物濫用治療市場分析

第7章：歐洲藥物濫用治療市場分析

第8章：亞太地區藥物濫用治療市場分析

第9章：中東和非洲藥物濫用治療市場分析

第10章：南美藥物濫用治療市場分析

第11章：公司簡介

  • Accord Healthcare
  • Amphastar Pharmaceuticals
  • BioCorRx
  • Cipla
  • Glenmark
  • LFB Group
  • Lupin
  • Mylan Laboratories
  • Opiant Technologies
  • Sanofi Aventis
  • Sanquin.
  • Sun Pharma
  • Teva Pharmaceutical
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA04261753

The substance abuse treatment market is experiencing rapid expansion, with its value estimated at USD 15.72 billion in 2025 and projected to reach USD 39.49 billion by 2035. This growth reflects a strong compound annual growth rate (CAGR) of 9.65% over the forecast period from 2026 to 2035, underscoring the increasing scale and urgency of addressing substance use disorders worldwide.

Several key factors are driving this upward trajectory. Rising addiction rates across diverse populations have significantly expanded the patient pool, creating sustained demand for both inpatient and outpatient treatment services. At the same time, technological advancements-such as telehealth platforms, digital therapeutics, and data-driven care models-are transforming how treatment is delivered, improving accessibility and patient outcomes.

Noteworthy Market Developments

The substance abuse treatment market has undergone a significant structural transformation, shifting from a highly fragmented ecosystem of small, independent providers to a more consolidated landscape dominated by a handful of large, influential players. This evolution has given rise to an oligopolistic environment, where scaled, omni-channel healthcare organizations and well-capitalized digital disruptors now exert substantial control over regional pricing, service delivery models, and clinical standards.

Among the key players shaping this new market dynamic are Acadia Healthcare and Universal Health Services, both of which are driving top-line growth through large-scale joint ventures and strategic expansion initiatives. Their extensive facility networks and operational scale allow them to optimize costs, expand access, and strengthen their competitive positioning across multiple regions. In the non-profit segment, the Hazelden Betty Ford Foundation has established dominance in the premium tier by offering high-quality, brand-driven care that appeals to patients seeking comprehensive and reputable treatment programs.

At the same time, newer, innovation-driven entrants such as Groups Recover Together are reshaping the outpatient medication-assisted treatment (MAT) space. By leveraging technology-enabled care delivery and scalable outpatient models, these organizations are redefining accessibility and efficiency in addiction treatment.

Core Growth Drivers

The demand for substance abuse treatment is increasing at an unprecedented pace, driven by a rapidly expanding consumer base and a continued lack of accessible, timely care. Across the globe, an estimated 39.5 million individuals are affected by severe drug use disorders, highlighting the vast scale of the issue and the urgent need for effective treatment infrastructure. Despite growing awareness and policy attention, many regions still struggle with insufficient capacity, limited funding, and barriers to access that prevent individuals from receiving the care they need.

Emerging Opportunity Trends

The Gen Z population is entering the substance abuse treatment market with uniquely complex clinical profiles, often marked by high rates of synthetic polysubstance use and severe co-occurring mental health conditions, including clinical depression and acute anxiety disorders. Unlike previous cohorts, this generation places a premium on care models that are not only clinically effective but also trauma-informed, culturally sensitive, and responsive to diverse identities. They expect treatment environments that are tech-enabled, streamlined, and explicitly LGBTQ+ affirming, reflecting broader societal shifts toward inclusivity and personalization in healthcare.

Barriers to Optimization

The most significant barrier to scaling operations in the substance abuse treatment market is the acute shortage of qualified human capital. The industry currently experiences a 25% supply gap in essential clinical roles, including Addiction Psychiatrists, Psychiatric Nurse Practitioners, and Licensed Clinical Social Workers (LCSWs). This persistent deficit has put considerable pressure on staffing models, creating a ripple effect throughout operational and financial structures. Over the past three years, the scarcity of skilled professionals has driven clinical wage inflation up by approximately 18%, further straining budgets and increasing the cost of care delivery.

Detailed Market Segmentation

By Treatment Type, the tobacco, nicotine, and vaping segment emerged as the dominant treatment category in the substance abuse market, capturing a 34.26% share and surpassing traditional substances such as opioids and alcohol. This leadership is largely attributed to growing public health concerns surrounding nicotine addiction and vaping-related lung injuries, which have drawn widespread attention from both healthcare providers and regulators. The surge in awareness, coupled with escalating rates of vaping among adolescents and young adults, has created a substantial demand for structured treatment interventions.

By End Use, hospitals accounted for more than 44% of revenue, establishing themselves as the leading end-use segment. Their prominence is largely driven by their ability to manage high-acuity cases, particularly complex polysubstance overdoses involving substances like xylazine-fentanyl combinations, which have increasingly strained emergency departments. Hospitals are uniquely equipped to provide continuous, round-the-clock care, enabling rapid detoxification, ventilatory support, and the integration of psychiatric services, all of which are critical for stabilizing patients in severe crises.

Segment Breakdown

By Treatment Type

  • Tobacco/Nicotine and Vaping
  • Alcohol
  • Marijuana
  • Synthetic Cannabinoids
  • Prescription and Over-the-counter Medications
  • Others

By End-use

  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • The Asia-Pacific region is emerging as a formidable force in the global market, poised to achieve an industry-leading compound annual growth rate (CAGR) of 9.5%. Historically, the region's growth in this sector was constrained by deep-seated cultural stigmas surrounding mental health, as well as strict, often punitive, governmental policies related to drug use and psychological treatment.
  • However, this landscape is undergoing a rapid transformation. By 2026, the rise of a wealthier middle class across countries such as India and several Southeast Asian nations is providing more disposable income that can be allocated toward healthcare and mental wellness services. This economic shift, combined with vigorous government-led campaigns aimed at reducing mental health stigma, has fueled a surge in demand for professional care.
  • In parallel, the digital revolution is enabling new modes of access and treatment, with localized therapy apps and telehealth platforms gaining popularity. These tools not only address geographic and social barriers but also cater to the tech-savvy younger demographic seeking discreet and convenient mental health support. Together, these economic, social, and technological shifts are positioning Asia-Pacific as a sleeper giant in the mental health and wellness industry.

Leading Market Participants

  • Accord Healthcare
  • Amphastar Pharmaceuticals
  • Apotex
  • BioCorRx
  • Cipla
  • Glenmark
  • INSYS Therapeutics
  • LFB Group
  • Lupin
  • Mylan Laboratories
  • Opiant Technologies
  • Sanofi Aventis
  • Sanquin.
  • Sterinova
  • Sun Pharma
  • Teva Pharmaceutical
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Substance Abuse Treatment Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Substance Abuse Treatment Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Materials (Active Pharmaceutical Ingredients, Excipients)
    • 3.1.2. Drug Development & Formulation (Detox Medications, MAT Therapies)
    • 3.1.3. Manufacturing (Tablets, Injectables, Implants)
    • 3.1.4. Treatment Program Development (Inpatient, Outpatient, Behavioral Therapy)
    • 3.1.5. Service Providers (Rehabilitation Centers, Hospitals, Clinics)
    • 3.1.6. Distribution Channels (Pharmacies, Online Platforms, Institutional Supply)
    • 3.1.7. End User (Patients, Rehab Centers, Healthcare Providers)
  • 3.2. Industry Outlook
    • 3.2.1. Global Epidemiology of Substance Use Disorders
    • 3.2.2. Treatment Landscape (Pharmacological vs Behavioral Therapy Mix)
    • 3.2.3. Healthcare Infrastructure for Addiction Treatment (Rehab Centers, Clinics Availability)
    • 3.2.4. Adoption of Treatment Modalities (Inpatient vs Outpatient vs Digital Care)
    • 3.2.5. Role of Public vs Private Sector in Treatment Delivery
    • 3.2.6. Pipeline Landscape (Emerging Therapies & Clinical Developments)
    • 3.2.7. Reimbursement Scenario & Insurance Coverage
    • 3.2.8. Regulatory & Policy Landscape
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Treatment Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Substance Abuse Treatment Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Rising Global Prevalence of Substance Use Disorders (SUDs) with a Large Untreated Population
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Tobacco/Nicotine and Vaping
        • 5.2.1.1.2. Alcohol
        • 5.2.1.1.3. Marijuana
        • 5.2.1.1.4. Synthetic Cannabinoids
        • 5.2.1.1.5. Prescription and Over-the-counter Medications
        • 5.2.1.1.6. Others
    • 5.2.2. By End-Use
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Hospitals
        • 5.2.2.1.2. Clinics
        • 5.2.2.1.3. Rehabilitation Centers
        • 5.2.2.1.4. Others
    • 5.2.3. By Region
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. North America
          • 5.2.3.1.1.1. The U.S.
          • 5.2.3.1.1.2. Canada
          • 5.2.3.1.1.3. Mexico
        • 5.2.3.1.2. Europe
          • 5.2.3.1.2.1. Western Europe
            • 5.2.3.1.2.1.1. The UK
            • 5.2.3.1.2.1.2. Germany
            • 5.2.3.1.2.1.3. France
            • 5.2.3.1.2.1.4. Italy
            • 5.2.3.1.2.1.5. Spain
            • 5.2.3.1.2.1.6. Rest of Western Europe
          • 5.2.3.1.2.2. Eastern Europe
            • 5.2.3.1.2.2.1. Poland
            • 5.2.3.1.2.2.2. Russia
            • 5.2.3.1.2.2.3. Rest of Eastern Europe
        • 5.2.3.1.3. Asia Pacific
          • 5.2.3.1.3.1. China
          • 5.2.3.1.3.2. India
          • 5.2.3.1.3.3. Japan
          • 5.2.3.1.3.4. South Korea
          • 5.2.3.1.3.5. Australia & New Zealand
          • 5.2.3.1.3.6. ASEAN
            • 5.2.3.1.3.6.1. Indonesia
            • 5.2.3.1.3.6.2. Malaysia
            • 5.2.3.1.3.6.3. Thailand
            • 5.2.3.1.3.6.4. Singapore
            • 5.2.3.1.3.6.5. Rest of ASEAN
          • 5.2.3.1.3.7. Rest of Asia Pacific
        • 5.2.3.1.4. Middle East & Africa
          • 5.2.3.1.4.1. UAE
          • 5.2.3.1.4.2. Saudi Arabia
          • 5.2.3.1.4.3. South Africa
          • 5.2.3.1.4.4. Rest of MEA
        • 5.2.3.1.5. South America
          • 5.2.3.1.5.1. Argentina
          • 5.2.3.1.5.2. Brazil
          • 5.2.3.1.5.3. Rest of South America

Chapter 6. North America Substance Abuse Treatment Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Treatment Type
    • 6.2.2. By End-Use
    • 6.2.3. By Country

Chapter 7. Europe Substance Abuse Treatment Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Treatment Type
    • 7.2.2. By End-Use
    • 7.2.3. By Country

Chapter 8. Asia Pacific Substance Abuse Treatment Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Treatment Type
    • 8.2.2. By End-Use
    • 8.2.3. By Country

Chapter 9. Middle East & Africa Substance Abuse Treatment Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Treatment Type
    • 9.2.2. By End-Use
    • 9.2.3. By Country

Chapter 10. South America Substance Abuse Treatment Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Treatment Type
    • 10.2.2. By End-Use
    • 10.2.3. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Accord Healthcare
  • 11.2. Amphastar Pharmaceuticals
  • 11.3. BioCorRx
  • 11.4. Cipla
  • 11.5. Glenmark
  • 11.6. LFB Group
  • 11.7. Lupin
  • 11.8. Mylan Laboratories
  • 11.9. Opiant Technologies
  • 11.10. Sanofi Aventis
  • 11.11. Sanquin.
  • 11.12. Sun Pharma
  • 11.13. Teva Pharmaceutical
  • 11.14. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators